Department of Clinical and Experimental Epilepsy, University College London Institute of Neurology, London, United Kingdom.
Ophthalmology. 2012 Oct;119(10):2152-60. doi: 10.1016/j.ophtha.2012.05.009. Epub 2012 Jul 30.
To explore the relationship of peripapillary retinal nerve fiber layer (ppRNFL) thinning in individuals exposed to the antiepileptic drug vigabatrin with respect to 2 separate variables: cumulative vigabatrin exposure and severity of vigabatrin-associated visual field loss (VAVFL).
Cross-sectional observational study.
Subjects were older than 18 years, 129 with vigabatrin-treated epilepsy (vigabatrin-exposed group) and 87 individuals with epilepsy never treated with vigabatrin (nonexposed group).
All subjects underwent ppRNFL imaging using spectral-domain optical coherence tomography. Eighty-four vigabatrin-exposed individuals underwent Goldmann kinetic perimetry. The visual field examined from the right eye was categorized as normal (n = 47), mildly abnormal (n = 18), or moderately to severely abnormal (n = 19). In 91 vigabatrin-exposed individuals, the cumulative vigabatrin exposure could be ascertained: 41 subjects received 1000 g or less, 23 subjects received more than 1000 g but equal to or less than 2500 g, 16 subjects received more than 2500 g but equal to or less than 5000 g or less, and 11 subjects received more than 5000 g.
Differences in ppRNFL thickness across the twelve 30° sectors: (1) among all nonexposed individuals and all vigabatrin-exposed individuals, (2) between each vigabatrin-exposed group, according to cumulative vigabatrin exposure, and the nonexposed group, (3) among different vigabatrin-exposed subjects grouped according to cumulative vigabatrin exposure, and (4) among vigabatrin-exposed subjects grouped according to severity of VAVFL.
The ppRNFL was significantly thinner in vigabatrin-exposed compared with nonexposed individuals in most 30° sectors (P<0.004). The temporal, temporal superior, and temporal inferior 30° sectors, as well as the nasal 30° sector, were not affected. There was a trend for increasing ppRNFL thinning with increasing cumulative vigabatrin exposure. The nasal-superior 30° sector was significantly thinner in group 1 (≤1000 g) compared with nonexposed individuals (P<0.05) and in vigabatrin-exposed individuals with normal visual fields compared with nonexposed individuals (P<0.05).
After vigabatrin exposure in individuals receiving cumulative doses of 1000 g or less or in the presence of normal visual fields, ppRNFL thinning in the nasal superior 30° sector may occur. With higher cumulative doses of vigabatrin exposure, additional ppRNFL thinning was observed. The temporal aspects of the ppRNFL are spared, even in individuals with large cumulative vigabatrin exposures and moderate or severe VAVFL.
探讨接受加巴喷丁治疗的个体中与周边视网膜神经纤维层(ppRNFL)变薄相关的 2 个独立变量:加巴喷丁累积暴露量和加巴喷丁相关视野缺损(VAVFL)的严重程度。
横断面观察性研究。
受试者年龄大于 18 岁,包括 129 例接受加巴喷丁治疗的癫痫患者(加巴喷丁暴露组)和 87 例从未接受加巴喷丁治疗的癫痫患者(未暴露组)。
所有受试者均接受光谱域光学相干断层扫描的 ppRNFL 成像。84 例加巴喷丁暴露的个体接受了 Goldmann 动态视野检查。右眼检查的视野分为正常(n = 47)、轻度异常(n = 18)或中度至重度异常(n = 19)。在 91 例加巴喷丁暴露的个体中,可以确定加巴喷丁的累积暴露量:41 例接受了 1000 g 或更少的药物,23 例接受了 1000 g 但等于或少于 2500 g 的药物,16 例接受了 2500 g 但等于或少于 5000 g 的药物,11 例接受了超过 5000 g 的药物。
在所有未暴露个体和所有加巴喷丁暴露个体之间,(1)在每个加巴喷丁暴露组之间,根据累积加巴喷丁暴露量与未暴露组进行比较,(2)在不同的加巴喷丁暴露个体之间,根据累积加巴喷丁暴露量进行分组,(3)在根据累积加巴喷丁暴露量分组的加巴喷丁暴露个体之间,以及(4)在根据 VAVFL 严重程度分组的加巴喷丁暴露个体之间,ppRNFL 厚度的差异。
与未暴露个体相比,加巴喷丁暴露个体的大多数 30°区域的 ppRNFL 明显变薄(P<0.004)。颞、颞上和颞下 30°区域以及鼻侧 30°区域不受影响。随着累积加巴喷丁暴露量的增加,ppRNFL 变薄呈趋势。与未暴露个体相比,第 1 组(≤1000 g)的鼻上 30°区域的 ppRNFL 明显变薄(P<0.05),与未暴露个体相比,正常视野的加巴喷丁暴露个体的 ppRNFL 也明显变薄(P<0.05)。
在接受累积剂量为 1000 g 或更少的加巴喷丁或存在正常视野的个体中,可能会发生鼻上侧 30°区域的 ppRNFL 变薄。随着累积加巴喷丁暴露量的增加,会观察到更多的 ppRNFL 变薄。即使在累积加巴喷丁暴露量较大且存在中度或重度 VAVFL 的个体中,ppRNFL 的颞侧区域也能幸免。